Ibrahim A Abdelhaleem1, Aml M Brakat2, Hoda M Adayel3, Moamen M Asla2, Marwa A Rizk2, Aya Y Aboalfetoh4. 1. Faculty of Medicine, Zagazig University, Zagazig City, Sharkia 44519, Egypt; International Medical Research Association IMedRA, Egypt. Electronic address: Ibrahim265862@medicine.zu.edu.eg. 2. Faculty of Medicine, Zagazig University, Zagazig City, Sharkia 44519, Egypt; International Medical Research Association IMedRA, Egypt. 3. Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt; International Medical Research Association IMedRA, Egypt. 4. Research and Development Department, Egyptian International Pharmaceutical Industries Company - EPICO, 10th of Ramadan City, Sharkia 44634, Egypt; International Medical Research Association IMedRA, Egypt.
Abstract
BACKGROUND: Type 2 diabetes mellitus (T2DM) is a progressive meta-inflammatory disorder, which induce micro and macrovascular complications. Resveratrol is a nutraceutical known to have antioxidant and anti-inflammatory properties. It improves insulin resistance; however, no clear evidence regarding its effects in patients with T2DM. OBJECTIVES: We aimed to evaluate the efficacy and the safety of oral resveratrol supplementation in type 2 diabetic patients concerning dose and duration. METHODS: We searched PubMed, Cochrane Library, Scopus, WOS, Wiley, and Google Scholar for RCTs evaluating the efficacy and safety of resveratrol on patients with T2DM. We screened the studies for the eligibility criteria, performed the quality assessment, extracted the studies' characteristics, baseline, and outcome data of interest, and finally conducted the meta-analysis using RevManV5.3. RESULTS: This systematic review and meta-analysis, including 17 RCTs with total 871 patients with T2DM, showed that resveratrol was superior to placebo on fasting blood glucose (FBG) and total cholesterol (TC) with doses ≥500mg {MD=-13.34, 95%CI [-22.73, -3.95], P=0.005}, {MD=-5.64, 95%CI [-6.95, -4.33], P<0.00001} respectively. Moreover, it improved HbA1c at three months {MD=-0.41, 95%CI [-0.65, -0.16], P=0.001 and systolic blood pressure {MD: -7.91, 95%CI [-10.44, -5.37], P<0.00001}. CONCLUSION: We concluded that resveratrol beneficially modulates glycemic control as well as cardiometabolic parameters in patients with T2DM.
BACKGROUND: Type 2 diabetes mellitus (T2DM) is a progressive meta-inflammatory disorder, which induce micro and macrovascular complications. Resveratrol is a nutraceutical known to have antioxidant and anti-inflammatory properties. It improves insulin resistance; however, no clear evidence regarding its effects in patients with T2DM. OBJECTIVES: We aimed to evaluate the efficacy and the safety of oral resveratrol supplementation in type 2 diabetic patients concerning dose and duration. METHODS: We searched PubMed, Cochrane Library, Scopus, WOS, Wiley, and Google Scholar for RCTs evaluating the efficacy and safety of resveratrol on patients with T2DM. We screened the studies for the eligibility criteria, performed the quality assessment, extracted the studies' characteristics, baseline, and outcome data of interest, and finally conducted the meta-analysis using RevManV5.3. RESULTS: This systematic review and meta-analysis, including 17 RCTs with total 871 patients with T2DM, showed that resveratrol was superior to placebo on fasting blood glucose (FBG) and total cholesterol (TC) with doses ≥500mg {MD=-13.34, 95%CI [-22.73, -3.95], P=0.005}, {MD=-5.64, 95%CI [-6.95, -4.33], P<0.00001} respectively. Moreover, it improved HbA1c at three months {MD=-0.41, 95%CI [-0.65, -0.16], P=0.001 and systolic blood pressure {MD: -7.91, 95%CI [-10.44, -5.37], P<0.00001}. CONCLUSION: We concluded that resveratrol beneficially modulates glycemic control as well as cardiometabolic parameters in patients with T2DM.